Literature DB >> 22151310

Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice.

Chih-Wei Lin1, Ih-Jen Su, Jia-Ru Chang, Yih-Yuan Chen, Jang-Jih Lu, Horng-Yunn Dou.   

Abstract

Mycobacterium tuberculosis (MTB) continues to be a leading cause of human deaths due to an infectious agent. Current efforts are focused on making better TB vaccines. We describe the generation and immunological characterization of recombinant BCG (rBCG). This rBCG was generated by incorporating an expression plasmid encoding two mycobacterial antigens (Ag85B and CFP10) and human interleukin (IL)-12 into a BCG strain. Immunogenicity studies in mice showed that rBCG coexpressing Ag85B, CFP10, and IL-12 (rBCG::Ag85B-CFP10-IL-12) induces a robust immune response in mice. The rBCG vaccine promotes a T-cell response against MTB that is characterized by a high proportion of polyfunctional and memory T cells in spleen and lung. Our results showed strong immunogenicity and mycobacterial growth inhibition of rBCG::Ag85B-CFP10 plus IL-12 than that of BCG vaccine.
© 2011 The Authors. APMIS © 2011 APMIS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22151310     DOI: 10.1111/j.1600-0463.2011.02815.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  12 in total

Review 1.  Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors:  Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

Review 2.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Authors:  Akhil Muthigi; Arvin K George; Sam J Brancato; Piyush K Agarwal
Journal:  Ther Adv Urol       Date:  2016-02-09

Review 3.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

4.  Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.

Authors:  Bryan E Hart; Laura P Hale; Sunhee Lee
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

5.  A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis.

Authors:  Adeliane Castro da Costa; Abadio de Oliveira Costa-Júnior; Fábio Muniz de Oliveira; Sarah Veloso Nogueira; Joseane Damaceno Rosa; Danilo Pires Resende; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

6.  Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis.

Authors:  Xuezhi Wang; Shuangshuang Chen; Yongjuan Xu; Huajun Zheng; Tongyang Xiao; Yuqing Li; Xing Chen; Mingxiang Huang; Haifeng Zhang; Xijing Fang; Yi Jiang; Machao Li; Haican Liu; Kanglin Wan
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

Review 7.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.

Authors:  Kai Ling Chin; Fadhilah Zulkipli Anis; Maria E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  J Immunol Res       Date:  2017-06-20       Impact factor: 4.818

Review 8.  Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory.

Authors:  Adeliane Castro da Costa; Sarah Veloso Nogueira; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Front Immunol       Date:  2014-04-07       Impact factor: 7.561

9.  Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.

Authors:  Bryan E Hart; Sunhee Lee
Journal:  PLoS Negl Trop Dis       Date:  2016-12-12

10.  Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity.

Authors:  Shiu-Ju Yang; Yih-Yuan Chen; Chih-Hao Hsu; Chia-Wei Hsu; Chun-Yu Chang; Jia-Ru Chang; Horng-Yunn Dou
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.